Pharmacokinetics of Diltiazem in Severe Renal Failure
Overview
Affiliations
The acute effects of a single dose of diltiazem (Tildiem), a calcium antagonist, were studied in 9 patients with severely impaired renal function (GFR between 0.03 and 0.87 ml/s/1.73 m2). Control measurements were made of inulin and PAH clearance, creatinine, blood pressure, heart rate and ECG. Following administration of diltiazem 120 mg, 7 blood samples were collected in the first 12 h and after 24 h, 32 h, 48 h; urine was collected for the first 12 h, 12-24 h and 24-48 h, and blood pressure, heart rate and ECG were recorded after 6 h. Diltiazem and its main metabolite, desacetyldiltiazem, had a pharmacokinetic profile similar to that in patients with normal renal function (peak plasma concentration, half-life and urinary excretion). Diltiazem is normally eliminated in the urine to a small extent, because it is metabolized, and this also applies to desacetyldiltiazem, which is probably further metabolized.
Brenes J, Cha Y Open Cardiovasc Med J. 2013; 7:23-6.
PMID: 23847692 PMC: 3680986. DOI: 10.2174/1874192401307010023.
Clinical pharmacokinetics of vasodilators. Part I.
Kirsten R, Nelson K, Kirsten D, Heintz B Clin Pharmacokinet. 1998; 34(6):457-82.
PMID: 9646008 DOI: 10.2165/00003088-199834060-00003.
Pharmacokinetics of verapamil in patients with renal failure.
Mooy J, Schols M, v Baak M, v Hooff M, Muytjens A, Rahn K Eur J Clin Pharmacol. 1985; 28(4):405-10.
PMID: 4029246 DOI: 10.1007/BF00544358.
Diltiazem. A review of its pharmacological properties and therapeutic efficacy.
Chaffman M, Brogden R Drugs. 1985; 29(5):387-454.
PMID: 3891302 DOI: 10.2165/00003495-198529050-00001.
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
Echizen H, Eichelbaum M Clin Pharmacokinet. 1986; 11(6):425-49.
PMID: 3542336 DOI: 10.2165/00003088-198611060-00002.